Vasiliki Bistola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8968938/publications.pdf

Version: 2024-02-01

448610 445137 1,148 47 19 33 citations h-index g-index papers 48 48 48 1682 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Cognitive impairment in heart failure: clinical implications, tools of assessment, and therapeutic considerations. Heart Failure Reviews, 2022, 27, 993-999.	1.7	11
2	Endothelial glycocalyx integrity in oncological patients. International Journal of Cardiology, 2022, 360, 62-67.	0.8	2
3	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp> . European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
4	Association between upâ€titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181.	2.9	11
5	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Failure Reviews, 2021, 26, 861-879.	1.7	16
6	Safety and efficacy of salt substitution with a low sodium-potassium enriched dietary salt in patients with heart failure with reduced ejection fraction: A pilot study. Clinical Nutrition ESPEN, 2020, 35, 90-94.	0.5	14
7	Cardiovascular disease in women: Executive summary of the expert panel statement of women in cardiology of the hellenic cardiological society. Hellenic Journal of Cardiology, 2020, 61, 362-377.	0.4	7
8	Vitamin B12 deficiency in heart failure: another "brick in the wall― Hellenic Journal of Cardiology, 2020, 61, 338-340.	0.4	0
9	A novel strategy for the management of lung congestion: targeting <scp>TRPV4</scp> channel, the †gate keeper' of pulmonary capillary permeability. European Journal of Heart Failure, 2020, 22, 1646-1648.	2.9	0
10	Global Longitudinal Strain of the Systemic Ventricle Is Correlated with Plasma Galectin-3 and Predicts Major Cardiovascular Events in Adult Patients with Congenital Heart Disease. Medicina (Lithuania), 2020, 56, 305.	0.8	6
11	Inotropic agents in cardiogenic shock. Current Opinion in Critical Care, 2020, Publish Ahead of Print, 403-410.	1.6	3
12	Lung ultrasound for the diagnosis of acute heart failure: time to upgrade current indication?. European Journal of Heart Failure, 2019, 21, 767-769.	2.9	10
13	Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice. Cardiac Failure Review, 2019, 5, 133-139.	1.2	34
14	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. Heart Failure Reviews, 2018, 23, 377-388.	1.7	16
15	Congestion in acute heart failure with reduced vs. preserved left ventricular ejection fraction: differences, similarities and remaining gaps. European Journal of Heart Failure, 2018, 20, 748-750.	2.9	5
16	Natriuretic peptides in acute coronary syndromes: A new role to predict recurrent ischemic event-related mortality?. Hellenic Journal of Cardiology, 2018, 59, 119-121.	0.4	2
17	Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor cells, CD34+ cells and vascular endothelial growth factorâ€A in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2018, 20, 1162-1163.	2.9	2
18	Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clinical Research in Cardiology, 2018, 107, 76-86.	1.5	15

#	Article	IF	Citations
19	Implantable devices to monitor patients with heart failure. Heart Failure Reviews, 2018, 23, 849-857.	1.7	4
20	Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. Journal of Cardiovascular Medicine, 2017, 18, 771-773.	0.6	9
21	Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clinical Research in Cardiology, 2017, 106, 359-368.	1.5	57
22	Nitroxyl donors for acute heart failure: promising newcomers. European Journal of Heart Failure, 2017, 19, 1333-1334.	2.9	8
23	Non-obstructive left ventricular assist device outflow thrombus: What is the appropriate management?. International Journal of Cardiology, 2016, 214, 33-34.	0.8	3
24	Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience. International Journal of Cardiology, 2016, 223, 781-784.	0.8	9
25	Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure. Expert Review of Clinical Pharmacology, 2016, 9, 513-523.	1.3	7
26	Prognostic value of in-hospital change in cystatin C in patients with acutely decompensated heart failure and renal dysfunction. International Journal of Cardiology, 2015, 182, 74-76.	0.8	15
27	Acute Heart Failure Syndromes in the Elderly. Heart Failure Clinics, 2015, 11, 637-645.	1.0	18
28	Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. International Journal of Cardiology, 2015, 180, 46-49.	0.8	35
29	Clinical and neurohormonal correlates and prognostic value of serum prolactin levels in patients with chronic heart failure. European Journal of Heart Failure, 2013, 15, 1122-1130.	2.9	23
30	Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure. International Journal of Cardiology, 2012, 157, 31-37.	0.8	5
31	Acute heart failure in patients with diabetes mellitus: Clinical characteristics and predictors of in-hospital mortality. International Journal of Cardiology, 2012, 157, 108-113.	0.8	51
32	Lymphocyte activation and apoptotic process in acute coronary syndromes. International Journal of Cardiology, 2011, 147, 449-450.	0.8	1
33	Prognostic Value of Tissue Doppler Right Ventricular Systolic and Diastolic Function Indexes Combined With Plasma B-Type Natriuretic Peptide in Patients With Advanced Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2010, 105, 249-254.	0.7	33
34	Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. International Journal of Cardiology, 2010, 139, 75-79.	0.8	23
35	Selfâ€assessment of health status is associated with inflammatory activation and predicts longâ€term outcomes in chronic heart failure. European Journal of Heart Failure, 2009, 11, 163-169.	2.9	51
36	Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. European Journal of Heart Failure, 2009, 11, 967-972.	2.9	33

3

#	Article	IF	CITATIONS
37	Clinical and Prognostic Value of Duke's Activity Status Index Along With Plasma B-Type Natriuretic Peptide Levels in Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2009, 103, 73-75.	0.7	41
38	Usefulness of Dobutamine-Induced Changes of the Two-Dimensional Longitudinal Deformation Predict Clinical and Neurohumoral Improvement in Men After Levosimendan Treatment in Acutely Decompensated Chronic Heart Failure. American Journal of Cardiology, 2008, 102, 1225-1229.	0.7	6
39	Long-term primary cultures of human adult atrial cardiac myocytes: Cell viability, structural properties and BNP secretion in vitro. International Journal of Cardiology, 2008, 131, 113-122.	0.8	22
40	Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis, 2008, 197, 278-282.	0.4	70
41	Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opinion on Investigational Drugs, 2008, 17 , $1143-1150$.	1.9	38
42	Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure. Heart, 2008, 94, 585-589.	1.2	51
43	Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. European Journal of Heart Failure, 2007, 9, 1172-1177.	2.9	32
44	Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis, 2007, 195, e210-e215.	0.4	54
45	Effects of Levosimendan on Quality of Life and Emotional Stress in Advanced Heart Failure Patients. Cardiovascular Drugs and Therapy, 2007, 21, 263-268.	1.3	20
46	Effects of Levosimendan on Right Ventricular Function in Patients With Advanced Heart Failure. American Journal of Cardiology, 2006, 98, 1489-1492.	0.7	103
47	Giant unruptured aneurysm of right valsalva sinus detected by magnetic resonance imaging. International Journal of Cardiology, 2004, 96, 299-301.	0.8	12